Huang, D. Q. et al. Global epidemiology of cirrhosis—aetiology, trends and predictions. Nat. Reef. Gastroenterol. Hepatol. 20388–398 (2023).
Google Scholar
Ginès, P. et al. Liver cirrhosis. Lancet 3981359–1376 (2021).
Google Scholar
Schwarz, M. et al. Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes. PLoS ONE 18e0290352 (2023).
Google Scholar
Patel, K. M. et al. Missed and delayed diagnoses of chronic liver disease in primary care patients with cirrhosis. Dig. Dis. Sci. https://doi.org/10.1007/s10620-024-08601-8 (2024).
Thiele, M. et al. Screening for liver fibrosis: lessons from colorectal and lung cancer screening. Nat. Reef. Gastroenterol. Hepatol. 21517–527 (2024).
Google Scholar
Ginès, P. et al. Screening for liver fibrosis in the general population: a call for action. Lancet Gastroenterol. Hepatol. 1256–260 (2016).
Google Scholar
Ginès, P. et al. Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases. Hepatology 75219–228 (2022).
Google Scholar
Serra-Burriel, M. et al. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet 402988–996 (2023).
Google Scholar
Newsome, P. N. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5362–373 (2020).
Google Scholar
Ginès, P. et al. Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project. Night. With. 29774–775 (2023).
Google Scholar
Møller, S. & Henriksen, J. H. Cardiovascular complications of cirrhosis. Gut 57268–278 (2008).
Google Scholar
Gaskari, S. A., Honar, H. & Lee, S. S. Therapy insight: cirrhotic cardiomyopathy. Nat. Clin. Pract. Gastroenterol. Hepatol. 3329–337 (2006).
Google Scholar
Ahn, J. C. et al. Development of the AI-cirrhosis-ECG score: an electrocardiogram-based deep learning model in cirrhosis. Am. J. Gastroenterol. 117424–432 (2022).
Google Scholar
Rattan, P. et al. Training and performance of an electrocardiogram-enabled machine learning model for detection of advanced chronic liver disease. Am. J. Gastroenterol. https://doi.org/10.14309/ajg.0000000000003433 (2025).
Attia, Z. I. et al. Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction. Night. With. 282497–2503 (2022).
Google Scholar
Yao, X. et al. Artificial intelligence-enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Night. With. 27815–819 (2021).
Google Scholar
Attia, Z. I. et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Night. With. 2570–74 (2019).
Google Scholar
Noseworthy, P. A. et al. Artificial intelligence-guided screening for atrial fibrillation using electrocardiogram during sinus rhythm: a prospective non-randomised interventional trial. Lancet 4001206–1212 (2022).
Google Scholar
Abeysekera, K. W. M. et al. Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol. Hepatol. 983–91 (2024).
Google Scholar
American Diabetes Association Professional Practice Committee 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes–2024. Diabetes Care 47S179–S218 (2024).
Google Scholar
Rydén, L. et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 343035–3087 (2013).
Google Scholar
Ajmera, V. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol. 78471–478 (2023).
Google Scholar
Ciardullo, S., Monti, T. & Perseghin, G. High prevalence of advanced liver fibrosis assessed by transient elastography among US adults with type 2 diabetes. Diabetes Care 44519–525 (2021).
Google Scholar
Wongtrakul, W., Niltwat, S., Charatcharoenwitthaya, N., Karaketklang, K. & Charatcharoenwitthaya, P. Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J. Gastroenterol. Hepatol. https://doi.org/10.1111/jgh.16666 (2024).
Ahn, J. C. et al. Applications of the AI-cirrhosis-ECG (ACE) score for improving prediction of decompensation and liver-related outcomes in cirrhosis: a multi-cohort study. JHEP Rep. 7101356 (2025).
Google Scholar
Harman, D. J. et al. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open 5e007516 (2015).
Google Scholar
Caballería, L. et al. High Prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. Clin. Gastroenterol. Hepatol. 161138–1145.e5 (2018).
Google Scholar
Patel, K. et al. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD practice guideline. Hepatology https://doi.org/10.1097/hep.0000000000000842 (2024).
Graupera, I. et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin. Gastroenterol. Hepatol. 202567–2576.e6 (2022).
Google Scholar
Adams, L. A., Thiele, M. & Tsochatzis, E. A. Detecting at-risk steatotic liver disease and liver fibrosis in the community. Hepatology https://doi.org/10.1097/hep.0000000000001400 (2025).
Majumdar, A., Campos, S., Gurusamy, K., Pinzani, M. & Tsochatzis, E. A. Defining the minimum acceptable diagnostic accuracy of noninvasive fibrosis testing in cirrhosis: a decision analytic modeling study. Hepatology 71627–642 (2020).
Google Scholar
Tamaki, N. et al. Two-step strategy, FIB-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD. Clin. Gastroenterol. Hepatol. 21380–387.e3 (2023).
Google Scholar
Ford, I. & Norrie, J. Pragmatic trials. N. Engl. J. Med. 375454–463 (2016).
Google Scholar
Kjaergaard, M. et al. Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals. Clin. Gastroenterol. Hepatol. 221037–1047.e9 (2024).
Google Scholar
Avitabile, E. et al. Liver fibrosis screening increases alcohol abstinence. JHEP Rep. 6101165 (2024).
Google Scholar
Rogal, S. et al. Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis. Hepatology 712080–2092 (2020).
Google Scholar
Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390497–509 (2024).
Google Scholar
Poynard, T. et al. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Aliment. Pharmacol. Ther. 58888–902 (2023).
Google Scholar
Wen, A. et al. Desiderata for delivering NLP to accelerate healthcare AI advancement and a Mayo Clinic NLP-as-a-service implementation. NPJ Digit. With. 2130 (2019).
Google Scholar
Olofson, A. et al. Detection of Undiagnosed Liver Cirrhosis via Artificial Intelligence-Enabled Electrocardiogram (DULCE): rationale and design of a pragmatic cluster randomized clinical trial. contemp. Clin. Trials Commun. 45101494 (2025).
Google Scholar
Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 3851559–1569 (2021).
Google Scholar
Mózes, F. E. et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol. Hepatol. 8704–713 (2023).
Google Scholar
Thiele, M. et al. Accuracy of the enhanced liver fibrosis test versus fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology 1541369–1379 (2018).
Google Scholar
of Franchis, R., Bosch, J., Garcia-Tsao, G. J. Hepatol. 76959–974 (2022).
Google Scholar
Rinella, M. E. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 771797–1835 (2023).
Google Scholar
Liang, J. X. et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J. Hepatol. 79592–604 (2023).
Google Scholar
Furlan, A. et al. Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease. Am. J. Roentgenol. 214W20–W26 (2020).
Google Scholar
Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79516–537 (2023).
Google Scholar
Younossi, Z. M. et al. Prevalence and predictors of cirrhosis and portal hypertension in the United States. Hepatology https://doi.org/10.1097/hep.0000000000001243 (2025).
